Hollister Biosciences Inc. Announces Filing of Amended and Restated Interim Financial Statements and MD&A for the Three and Nine Months Ended September 30, 2020.

 
 

Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the " Company ") announces that as a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure.

 
 

  Hollister Biosciences Inc. Logo (CNW Group/Hollister Biosciences Inc.) 

 
 

The unaudited condensed interim consolidated financial statements and interim MD&A of the Company for the three and nine months ended September 30, 2020 and 2019 ("Q3 2020 Financial Statements and MD&A) have been amended and restated in order to correct for certain disclosure deficiencies on the following items as listed below. Details of the changes are fully described in Note 20 to the amended and restated unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2020 and 2019 ("Amended Q3 2020 Financial Statements and MD&A") as filed on SEDAR on February 25, 2021 .

 

  Acquisitions  

 

The Amended Q3 2020 Financial Statements and MD&A have been restated and amended to disclose the circumstances that led to the incorrect accounting treatments for the acquisitions of Labtronix, Inc and AlphaMind Brands Inc., how and from when the errors have been corrected.

 

  Change in accounting treatment for the acquisition of Labtronix, Inc.  

 

The Company received the preliminary independent valuation report on the fair values of the net assets acquired. As a result, and as part of these amended condensed interim consolidated financial statements for the three and nine months ended September 30, 2020 , the Company is restating its purchase price allocation of the Venom Extracts acquisition (Note 4(a)). More specifically, the fair value of the consideration paid has been revised from $0.035   (C$0.05) per Payment Share and Earn-Out Share to $0.063   (C$0.092) per Payment Share and Earn-Out Share, resulting in total consideration increasing from $3,450,442 to $6,328,112 . The revised fair value is primarily driven by using the Company's one-month volume weighted average price to determine the consideration paid rather than the share price on the date of the acquisition, which was adversely impacted by the COVID-19 pandemic. Additionally, as a result of the valuation report, the Company has recorded brand as an acquired intangible asset with a fair value of $1,149,552 and acquired intellectual property with a fair value of $1,451,062 . As a result of the increased fair value of consideration paid and additional intangible assets acquired, the fair value of acquired goodwill increased from $2,920,400 to $3,197,456  

 

  Change in accounting treatment for the acquisition of AlphaMind Brands Inc.  

 

The Company determined that AlphaMind did not have any intangible assets (intellectual property) given the absence of proprietary formulations and other material intellectual property and accordingly revised its accounting treatment of the acquisition from an asset acquisition (as described above) to an acquisition expense. As a result of the change in accounting treatment from an asset acquisition to an acquisition expense, the excess consideration paid over net assets acquisition was recorded as an expense in the unaudited consolidated statement of loss and comprehensive loss, which reduced the intellectual property associated with the AlphaMind acquisition as previously reported in the Company's unaudited consolidated financial statements for the three and nine months ended September 30, 2020 from $535,478 to $nil.

 

  U.S. marijuana-related activities  

 

The September 30, 2020 interim MD&A has been amended and restated to provide the disclosure required pursuant to CSA Staff Notice 51-352 (Revised) Issuers with U.S. Marijuana-Related Activities . This information is material for readers to understand the company's U.S. marijuana operations and the related risks.

 

  News releases and non-GAAP financial measures  

 

As part of the review by the British Columbia Securities Commission, the following news releases were not compliant with the requirements of CSA Staff Notice 52-306 (Revised) for non-GAAP financial measures and should not be relied upon: February 25, 2020 , March 6, 2020 , March 30, 2020 , June 2, 2020 , June 11, 2020 , July 14, 2020 , October 27, 2020 , December 10, 2020 , January 7, 2021 , and January 25, 2021 .

 

   About Hollister Biosciences Inc.   

 

Hollister Biosciences Inc. is a multi-state company with a portfolio of innovative, high-quality cannabis & hemp branded consumer products and white-labeling manufacturing.  Our products are sold in 370 dispensaries across Arizona and California . As of March 26   th , 2020 (see press release dated    March 30th, 2020    ), Hollister Biosciences acquired 100% of Venom Extracts, a category leading brand which sold over 4 million grams of product in 2020, accounting for up to 30 percent of category sales in Arizona .

 

  Website: www.hollistercannabisco.com   

 

   The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.   

 

  Forward-Looking Information: This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com   

 
 
 

SOURCE Hollister Biosciences Inc.

 

 

 

 Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/February2021/25/c5138.html  

 
 

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Glowing mushrooms with colorful graphs in the background on a dark surface.

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry.

However, the sector is seeing a resurgence of optimism in 2025 on the back of various US developments.

“The psychedelic industry in 2025 will likely see significant advancements in clinical applications, particularly in treating PTSD, depression, and addiction, as research continues to validate their therapeutic potential,” Dr. Markus Ploesser, chief innovation officer at Open Mind Health, told Microdose in January.

Keep reading...Show less
AVECHO BIOTECHNOLOGY

Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia

Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia. Avecho retains the rights to commercialise the product in all other territories, with Sandoz granted a first right of refusal for these markets. Avecho’s CBD capsule aims to be the first pharmaceutical CBD product registered with the Therapeutic Goods Administration (“TGA”) as an over-the-counter medicine, which market forecasts predict could generate sales surpassing US$125M per annum in Australia2.

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

 

  Compass management will host a conference call at 8:00 am ET (1:00pm UK)  

 

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Emyria Limited

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

Keep reading...Show less
Quantum Biopharm (CSE: QNTM)

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders


Keep reading...Show less

Latest Press Releases

Related News

×